Arthropathy News and Research RSS Feed - Arthropathy News and Research

Opioid use does not impair reverse shoulder arthroplasty success

Opioid use does not impair reverse shoulder arthroplasty success

Taking opioids prior to reverse shoulder arthroplasty does not hamper patients’ chances of having successful outcomes, researchers have found. [More]
EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Octapharma confirmed today the European Medicines Agency (EMA) has adopted a positive opinion towards human cell line recombinant human FVIII, Nuwiq®, recommending the granting of a marketing authorisation for the medicinal product for treatment and prophylaxis of bleeding (also during and after surgery) in paediatric and adult patients with haemophilia A (congenital FVIII deficiency). [More]
Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Using cholesterol-lowering statins may be associated with musculoskeletal conditions

Using cholesterol-lowering statins may be associated with musculoskeletal conditions, arthropathies (joint diseases) and injuries, according to a report published Online First by JAMA Internal Medicine, a JAMA Network publication. [More]
Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors. [More]
Sun exposure advice recommended for anti-TNF users

Sun exposure advice recommended for anti-TNF users

Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers. [More]
Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology. [More]
Bartonella bacterium may also play a role in human arthritis

Bartonella bacterium may also play a role in human arthritis

A bacterium historically associated with cat scratch fever and transmitted predominately by fleas may also play a role in human rheumatoid illnesses such as arthritis, according to new research from North Carolina State University. [More]
Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid. [More]
Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. [More]
Rush University Medical Center first to receive Octapharma grant under anniversary program

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine. [More]
Novo Nordisk re-launches its changing possibilities in hemophilia campaign

Novo Nordisk re-launches its changing possibilities in hemophilia campaign

Novo Nordisk Inc. announced the re-launch of its changing possibilities in hemophilia(TM) campaign through a rebranded Web site and a new community on Facebook®. People living with hemophilia face many daily challenges, and Novo Nordisk is committed to helping this community realize that there is also a lifetime of possibilities. [More]
Inhibitor Education Summits to address pertinent topics regarding hemophilia

Inhibitor Education Summits to address pertinent topics regarding hemophilia

More than 160 families of patients living with a rare form of hemophilia are coming together at educational summits sponsored this fall by the National Hemophilia Foundation (NHF) and the Center for Biomedical Continuing Education (CBCE). For the fifth year, the Inhibitor Education Summits will connect patients and their families with expert healthcare professionals and fellow patients to address pertinent topics such as effective pain management, exercise and nutrition, financial security, and psychological wellbeing. [More]
Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS). [More]
Prophylaxis effective at preventing joint bleeds and preserving joint function and structure in young boys with hemophilia A

Prophylaxis effective at preventing joint bleeds and preserving joint function and structure in young boys with hemophilia A

According to a new landmark study published in The New England Journal of Medicine, infusions of clotting factor VIII used preventively can significantly reduce the risk of developing joint damage associated with joint bleeding in young children with hemophilia A. [More]
Experts call for improved access to treatment for psoriatic arthritis

Experts call for improved access to treatment for psoriatic arthritis

MPs gathered at the House of Commons on Tuesday (April 5th) as experts and patient groups urged members of parliament to lobby for improved access to treatment for patients with psoriatic arthritis, a little known and poorly understood condition in which patients experience symptoms of both psoriasis and arthritis. [More]
Mutations in the HFE gene directly associated with chronic joint disease

Mutations in the HFE gene directly associated with chronic joint disease

Mutations in the HFE gene, which is involved in iron regulation, seem to be directly associated with chronic joint disease (or haemophilic arthropathy) among haemophilic patients, claim a team of Portuguese scientists in the April issue of the journal Blood. [More]